You are here
Generic Actos Receives Approval
November 9, 2004
PITTSBURGH, Nov. 9 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL - News) today announced that the U.S. Food and Drug Administration has granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Pioglitazone Hydrochloride Tablets, 15 mg, 30 mg, and 45 mg.
Pioglitazone Hydrochloride Tablets are the generic version of Takeda Pharmaceuticals' Actos® Tablets.
For more information about Mylan, visit www.mylan.com .
Source: Mylan Laboratories Inc.
Almost 64% of Patients Showed Decreased Hemoglobin A1c Levels
Lifesaving Life Foam for Battlefield, Terrorist Attacks, Trauma
Cell Reprogramming Process May Benefit Patients Prone to Severe Hypoglycemia
Beagles Beat Out Advanced Technology
Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission